HIGH-EFFICIENCY QUANTITATIVE CONTROL OF MITOCHONDRIAL TRANSFER BASED ON DROPLET MICROFLUIDICS
20230407336 ยท 2023-12-21
Inventors
Cpc classification
B01L2200/0673
PERFORMING OPERATIONS; TRANSPORTING
B01L2200/0647
PERFORMING OPERATIONS; TRANSPORTING
B01L2300/0867
PERFORMING OPERATIONS; TRANSPORTING
C12N5/0658
CHEMISTRY; METALLURGY
B01L2400/086
PERFORMING OPERATIONS; TRANSPORTING
C12N15/87
CHEMISTRY; METALLURGY
B01L3/502761
PERFORMING OPERATIONS; TRANSPORTING
International classification
C12N15/87
CHEMISTRY; METALLURGY
B01L3/00
PERFORMING OPERATIONS; TRANSPORTING
C12N5/00
CHEMISTRY; METALLURGY
Abstract
A system for quantitative control of mitochondrial transfer based on droplet microfluidics includes a droplet generation module configured to generate droplets containing isolated mitochondria and a single cell; a droplet observation module configured for observation of the generated droplets under a microscope; and a droplet collection module configured to collect the generated droplets. The number of mitochondria needed to be transferred into recipient cells is an import issue in precise medicine. The development of the presented invention, which can achieve a precise quantity-control on mitochondrial transfer at the single cell level, can help us to determine the mitochondria number needed to make a significant function improvement on the recipient cells before conducting the cell therapy for mtDNA-related diseases.
Claims
1. A system for quantitative control of mitochondrial transfer based on droplet microfluidics, comprising: a droplet generation module configured to generate droplets containing isolated mitochondria and a single cell; a droplet observation module configured for observation of the generated droplets under a microscope; and a droplet collection module configured to collect the generated droplets.
2. The system according to claim 1, wherein the droplet generation and observation modules are connected by a conduit.
3. The system according to claim 1, wherein the system is disposed on a chip.
4. The system according to claim 4, wherein the chip is smaller than 8 cm in length.
5. The system according to claim 1, wherein the droplet generation module comprises three inlets.
6. The system according to claim 1, wherein the droplet generation module further comprises mitochondrial recipient cell suspension, isolated mitochondria suspension, and surfactant-added fluorinated oil.
7. The system according to claim 6, wherein the mitochondrial recipient cell is recipient C2C12 cell.
8. The system according to claim 1, wherein the droplet generation module comprises a flow-focusing structure configured to separate the mitochondrial recipient cell suspension and the isolated mitochondria suspension into droplets.
9. The system according to claim 8, wherein the droplet generation module comprises a wave-like structure which is configured to focus randomly distributed cells from the inlet to a line. The system according to claim 9, wherein the wave-like structure is configured to improve the single cell encapsulation ratio more than 47%.
11. The system according to claim 9, wherein the wave-like structure is configured to suppress the multiple cell encapsulation ratio less than 6%.
12. The system according to claim 1, wherein the droplet comprises isolated mitochondria and a single cell has a diameter of at less than 40 m.
13. The system according to claim 1, wherein an efficiency of mitochondrial transfer is at least 75%.
14. The system according to claim 1, wherein the system is configured to yield at least 210.sup.6 recipient cells in the droplets for mitochondria transfer in 30 minutes.
15. A method for quantitative control of mitochondrial transfer based on droplet microfluidics, comprising the steps of: preparing a first suspension, a second suspension, and an oil fluid; co-flowing of the first suspension, the second suspension, and the oil fluid to a system for quantitative control of mitochondrial transfer based on droplet microfluidics; co-encapsulating the first and the second suspensions in droplets; collecting the droplets; and co-culturing the first and the second suspensions in droplets.
16. The method according to claim 15, wherein the first suspension is a mitochondrial recipient cell suspension and the isolated mitochondria suspension.
17. The method according to claim 15, wherein the second suspension is an isolated mitochondria suspension.
18. The method according to claim 15, wherein the droplets have a diameter of at less than 40 m.
19. The method according to claim 15, wherein the system comprises a wave-like structure.
20. The method according to claim 15, wherein the wherein the droplets comprise mitochondria, mitochondrial recipient cell, and mitochondrial recipient cell with mitochondria inside.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0032]
[0033]
[0034]
[0035]
[0036]
DETAILED DESCRIPTION
[0037] Turning to the drawings in detail,
Microfluidic Chip Fabrication and Operations
[0038] The designed chip was fabricated using soft-lithography. Prior to experiments, the chip channels were coated with a surface modification agent to make them hydrophobic for stable water-in-oil droplet generation and transporting.
Cell Culture
[0039] C2C12 myoblasts were cultured in Dulbecco modified Eagle medium (DMEM) with high glucose (Gibco, 11965084) supplemented with 10% fetal bovine serum (Gibco, 12800058) and 1% Antibiotic-Antimycotic (Gibco, 15240096) at 37 C. in 5% CO.sub.2
Mitochondria Isolation
[0040] The mitochondria used in this work were freshly isolated from C2C12 myoblasts cells by following the protocol of mitochondria isolation kit (Beyotime, C3601) before each mitochondrial transfer experiment. First, the mitochondria of donor C2C12 cells were stained with MitoTracker Green FM (Invitrogen, M7514). Second, the stained cells were washed three times with PBS, detached from the culture flask with Trypsin/EDTA Solution (Gibco, R001100), and centrifuged at 500 g for 5 minutes. Third, the supernatant was removed, and the collected cells were resuspended with 1 ml of cell lysis reagent (Beyotime, C3601-1) and placed in ice bath for 15 minutes. Fourth, the lysed cells were homogenized with a glass homogenizer for 30 cycles. Fifth, the homogenized cells were centrifuged at 1,000 g for 10 minutes at 4 C. Then, the supernatant was resuspended with 1 ml of cell lysis reagent (Beyotime, C3601-1) and centrifuged at 1,000 g for 10 minutes at 4 C. again for more purity. Finally, the supernatant was collected and centrifuged at 3,500 g for 10 minutes at 4 C. The pellet collected was the isolated mitochondria. Mitochondria storage reagent (Beyotime, C3601-3) was used to suspend the isolated mitochondria at the required concentration for further experiments. The mitochondria isolated from 110.sup.6 cells and suspended in 10 L of mitochondria storing reagent was set as one unit of mitochondrial suspension.
3D Reconstruction of Cells and Mitochondria Under Confocal Fluorescence Microscope
[0041] After co-culturing the recipient cells and exogenous isolated mitochondria in droplets for 2 hours, the droplets were loaded into the observation module, as shown in
Droplet Rupture and Cell Collection
[0042] The collected droplets floated on the top the fluorinated oil. Before the droplets broke, the extra oil on the bottom of the tube was removed. Then, 1 ml of 50% 1H,1H,2H,2H-Perfluorooctanol (PFO, Thermo Scientific, AAB2015609) was added to the tube containing the collected droplets and gently vortexed for 1 minute for the droplets to merge into a bulk solution. Afterwards, the upper bulk solution was carefully moved to a new tube and centrifuged at 300 g for 3 minutes to collect the cells.
Myogenic Differentiation of C2C12
[0043] For evaluating C2C12 differentiation, 5,000 cell/cm.sup.2 were seeded in a six-well plate and cultured in growth media until reaching 80% confluence. The media were then replaced with DMEM (Gibco, 11965084) supplemented with 2% horse serum (Gibco, 16050130). The cells were kept in differentiation medium until the end of the assay, typically between day 5 to day 7. Myotube formation was monitored every two days. The time-points were days 0, 3, and 7.
MTT Assay
[0044] The cell proliferation rate of each C2C12 cell group was determined by MTT assay. In brief, C2C12 cells were plated at a density of 5,000 cell/cm.sup.2 in 96-well plates and incubated for 24 h. After incubation, the cells were treated with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, 100 L, 0.5 mg/mL) for 3 hours at 37 C. The produced dark blue formazan crystals were solubilized by 100 L DMSO. The absorbance at 570 nm was measured with a microplate reader.
[0045] In use, the developed droplet-based mitochondria transfer system of
[0046] As shown in
[0047] For the observation and 3D rebuilding under a confocal fluorescence microscope (LEICA SP8LIA++ TRUE Confocal Laser Scanning Microscope), MitoTracker Green FM (Invitrogen, M7514) at a concentration of 2 M is used to stain the mitochondria before isolation from donor cells.
[0048] As presented in
[0049] As mentioned above, the cell encapsulation efficiency is improved beyond the Poisson distribution by using the wave-like structure.
[0050] The closed microenvironment of droplets limits the travelling distance of isolated mitochondria and increases the probability of the isolated mitochondria to contact with the cell, thereby making mitochondria taken up by the cell easily, and improving the mitochondria transfer efficiency. Moreover, due to the smaller size of isolated mitochondria than that of the droplets (1-40 m in diameter), the isolated mitochondria are evenly encapsulated in each droplet. The number of isolated mitochondria encapsulated in droplets can be controlled by adjusting the concentration of isolated mitochondria suspension.
EXAMPLE
[0051] In one embodiment, three different concentrations of isolated mitochondrial suspension (0.25, 0.5, and 1.0 units of concentration) are used to verify the transfer efficiency of the present invention.
[0052] Myogenesis assay is performed to test the differentiation ability of C2C12 myoblasts after mitochondrial transfer with the proposed droplet microfluidics-based method. After 7 days of induction,
Industrial Applicability
[0053] The present invention provides a mitochondrial transfer based on droplet microfluidics system is provided as a high-efficiency quantitative mitochondrial transfer system due to the following advantages:
[0054] The number of mitochondria needed to be transferred into recipient cells is an import issue in precise medicine. The development of the presented invention, which can achieve a precise quantity-control on mitochondrial transfer at the single cell level, can help us to determine the mitochondria number needed to make a significant function improvement on the recipient cells before conducting the cell therapy for mtDNA-related diseases.
[0055] Compared to existing mitochondrial transfer methods, the invented method can produce massive quantitative mitochondria transferred cells for cell therapy purpose. Although the co-culture with isolated mitochondria method can also produce the number of cells needed for cell therapy, it cannot control the number of mitochondria transferred into each recipient cell, thus, some cells without enough mitochondria transferred may cannot fully play their therapeutic functions. However, using the invented system, the mitochondria transferred into each recipient cell is controlled, thus, the cells used for cell therapy can fully play their therapeutic functions.
[0056] While the present disclosure has been described and illustrated with reference to specific embodiments thereof, these descriptions and illustrations are not limiting. It should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the present disclosure as defined by the appended claims. The illustrations may not necessarily be drawn to scale. There may be distinctions between the artistic renditions in the present disclosure and the actual apparatus due to manufacturing processes and tolerances. There may be other embodiments of the present disclosure which are not specifically illustrated. The specification and the drawings are to be regarded as illustrative rather than restrictive. Modifications may be made to adapt a particular situation, material, composition of matter, method, or process to the objective, spirit and scope of the present disclosure. All such modifications are intended to be within the scope of the claims appended hereto. While the methods disclosed herein have been described with reference to particular operations performed in a particular order, it will be understood that these operations may be combined, sub-divided, or re-ordered to form an equivalent method without departing from the teachings of the present disclosure. Accordingly, unless specifically indicated herein, the order and grouping of the operations are not limitations.